Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push

FiercebiotechView source article

Part of story

Sobi and Innate Pharma Form $580M Partnership to Advance Lacutamab to Phase 3 for Rare Skin Cancer

Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced a strategic partnership worth up to $580 million, with $75 million upfront, to advance lacutamab into the TELLOMAK-3 Phase 3 confirmatory trial for cutaneous T-cell lymphoma, specifically Sézary syndrome. Innate Pharma also appointed Markus Jensen as Chief Medical Officer.

Aug 10, 2026·9 sources

Sobi and Innate Pharma Form $580M Partnership to Advance Lacutamab to Phase 3 for Rare Skin Cancer

Other sources for this story

Endpoints

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Biospace

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Webdisclosure

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

Stocktitan

Innate Pharma Names Markus Jensen Chief Medical Officer; Phase 3 Planned

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push — Fiercebiotech

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources